Skip To The Main Content
2023 PDA Annual Meeting

2023 PDA Annual Meeting

Apr 03 - Apr 05, 2023
New Orleans, LA

Back to the Future: Learning from the Past in a Patient-Centric World

  • Conference
  • The Americas
Register Now

Registration Options

Individual Registration

Proceed with In-Person Registration

Group Registration

Multi Registration Inquiry Form

left to save

Program Highlights
We are accepting more poster abstracts! The submission deadline is 10 February.

Early registration is going on now until 05 February, with up to $500 in savings!
Call for Abstracts

Overview

The PDA Annual Meeting is the premier meeting on pharmaceutical/biopharmaceutical manufacturing science and technology.

The 2023 theme “Back to the Future: Learning from The Past in A Patient-Centric World” will spotlight the critical connection between our patients and the manufacturing process and enabling a patient-focused mindset on the manufacturing floor.

This event provides a forum for sharing knowledge on developing new modalities and the adoption of innovative approaches and processes. You will dive into exciting interactive sessions designed for manufacturing leaders, technical experts/scientists, and early career professionals. No matter what your area of focus, you are sure to come away with tangible and practical solutions to improve your operations

Ask a Question
Promotional Tools

Agenda

  • Day 1
  • Day 2
  • Day 3

  • MONDAY, 03 APRIL

    13:00 – 15:00 | P1: Opening Plenary
    Moderator:     Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

    The EveryLife Foundation is a 501(c)(3) nonprofit, nonpartisan organization dedicated to empowering the rare disease (RD) patient community to advocate for impactful, science-driven legislation and policy that advances the equitable development of and access to lifesaving diagnoses, treatments, and cures. As part of its mission, the EveryLife Foundation undertook an initiative to understand the economic burden of RD by commissioning the Lewin Group to estimate the economic impact of RD in the U.S. in 2019. Julia Jenkins, Executive Director, will provide us with key takeaways from the study. Kelly Baker, a member of the Young Adult Rare Representatives (YARR) group, will share her perspective as a patient living with a rare disease. She will deliver a history of home parenteral nutrition and how it has changed significantly in an effort to improve both safety and patient quality of life.

    13:00 | Welcome from PDA Leadership and Meeting Co-Chairs
    Susan J. Schniepp, Chair, PDA Board of Directors and Distinguished Fellow, Regulatory Compliance Associates Inc.
    Glenn E. Wright, COO, PDA
    Amanda McFarland, MS, Senior Consultant, ValSource, Inc.
    Kenneth Paddock, Quality Director, Sterility Assurance, Baxter

    13:30 | Julia Jenkins, Executive Director, EveryLife Foundation for Rare Diseases

    14:10 | The Past, Present, and Future of Home Parenteral Nutrition: A Patient's Perspective
    Kelly A. Baker,     Young Adult Rare Representative, EveryLife Foundation for Rare Diseases

    14:30 | Q&A

    15:00 – 15:30 | Refreshment Break

    15:30 – 17:00 | P2: Digitization of Pharma
    Moderator: Kenneth Paddock,     Quality Director, Sterility Assurance, Baxter

    Cybersecurity has become increasingly visible, touching all aspects of our lives.  In healthcare, specifically, it involves the protection of electronic information and assets from unauthorized access, use, and disclosure. This informative session will address the three goals of cybersecurity: protecting the confidentiality, integrity, and availability of information. Hear from the experts regarding the issues that are going to confront healthcare organizations from a cyber risk perspective, whether it is patient security, supplier relationships, or external threats affecting data integrity. See how addressing security soft spots, understanding the bigger picture for patient safety, and providing a cybersecurity strategy for third-party risk management will provide the level of comfort patients deserve regarding their healthcare information.

    15:30 | Pamela Docherty, Digital Connectivity Executive, Siemens Industry

    15:55 | Vinicius Tarantino, Head of Digital Compliance and Protection, GxP-CC

    16:20 | Q&A

    17:00 – 19:00 | Grand Opening Celebration in Exhibit Hall

  • TUESDAY, 04 APRIL

    08:30 – 10:00 | P3: Emerging Technologies
    Moderator: Peter Makowenskyj, MEng, Director of Design Consulting, G-CON Manufacturing, Inc.

    Over the past decade, we have seen the emergence of many new and novel technologies in the biotech industry. But where do we head from here? Two of our industry thought leaders will discuss how their companies are pushing the boundaries of what is possible and accelerating the development of new drugs while paving their own path. They will provide a glimpse of how their companies will advance ATMPs into the future.

    08:30 | Moving Up the Central Dogma and Moore's Law in Biomanufacturing
    Hari Pujar, PhD, MBA, Operating Partner, Flagship Pioneering

    08:55 | Developing Allogeneic CAR and CAd γδ T-Cell Therapies to Fight Cancer
    Don Healey, PhD,     Chief Technology Officer, Adicet Bio

    08:30 | Q&A

    10:00 – 10:45 | Refreshment Break and Poster Presentations in Exhibit Hall

    10:45 – 12:15 | Concurrent Sessions

    A1
    Moderator: Diane Paskiet, MS, Director of Scientific Affairs, West Pharmaceutical Services, Inc.

    10:45 | Blind Spot: EU ATMP Regulation and the Annex 1 Revision
    Ryan Murray, Senior Consultant, ValSource, Inc.

    11:05 | Virus Retentive Filtration: 2023 Update
    Kurt Brorson, PhD, Vice President, Technical, Parexel International

    11:25 | ICH Q5A Revision: Quality Control Through Viral Contamination Risk Mitigation for Monoclonal Antibodies Drugs, Gene Therapies and Beyond
    Manjula Aysola, Sr. Regulatory Consultant, MilliporSigma

    11:45 | Q&A

    B1: Evaluation of New Technologies in Quality Control
    Moderator: Lauren Specchio, Microbiologist (RA III), Baxter

    Designing and building robust holistic contamination control strategies (CCS) is critical to the manufacture of sterile products. Come hear from Peter Bisp on how Novo Nordisk managed to develop a simple, yet comprehensive approach to evaluate the robustness of contamination control for a facility. Continuing on with new technology, Maik Jornitz will address and review new innovative technologies such as single-use process technologies and their benefits as a functionally closed system, isolator and isolator/robotic (isobot)-based aseptic filling systems, and new facility layouts that reduce the complexity of critical areas. The session will conclude with a presentation by  Richard Hall will discuss the ASTM E55 Clean by Design (CbD) task group. He will focus on  how they are developing a risk- and science-based consensus standard to attempt to address the issue of manufacturing systems that are specified, designed, manufactured, and tested without consideration of such factors as Clean in Place cleaning process development and validation, OPEX, production efficiency and capacity.  Through this presentation, you will  gain awareness of the very substantial improvements that are achievable.

    10:45 | Evaluation of Contamination Control Strategies in Novo Nordisk
    Peter Bisp, MA, QA Specialist, Novo Nordisk A/S

    11:05 | New Technologies Meeting the Focus on Contamination Control Strategies
    Maik Jornitz, CEO, G-CON Manufacturing

    11:25 | Clean by Design: Draft ASTM E55 Standard for the Specification, Design, Manufacture, and Test of (Bio-)Pharmaceutical Manufacturing Systems That are Easy to Clean in Place
    Richard K. Hall Hall, Business Development, Rattiinox S.r.l.

    11:45 | Q&A

    C1: Digitizing Data and Effective Management Strategies
    Moderator: Jason Kerr, MBS, MBA, Senior GXP Specialist, Redica Systems

    If the biopharmaceutical industry is able to evolve from scraping bark off of willow trees to hacking mRNA to manufacture proteins, why is it that some of us are still etching data onto a papyrus instead of leveraging digitized data? The industry needs to become more agile by linking disconnected databases in a centralized and standardized way in order to enable systematic review of the data. Only then can we unleash the potential to assess data across the board. In this session, the presenters will explore how to proactively identify the risks in using publicly available data to ensure continuous quality improvement, using eData to streamline the transfer of Quality information from suppliers to manufacturers, and automating real-time data to ensure a total risk-based contamination control strategy.

    10:45 | Use of Internal and Open-Source Quality Data Indicators for Continuous Quality Improvement and Risk Mitigation Strategies
    Deanna Anderson, Senior Director, Lachman Consultants
    Carrie Colella, Senior Director, Lachman Consultants

    11:05 | Increasing Agility Through Digitalization: A Case Study of E-Data Transfer for Quality and Regulatory Information in Supplier-Customer Relationships
    Marius Stoffels, Product Manager, Digital Solutions, Merck KGaA

    11:25 | True Digital Transformation of a Risk-Based Contamination Control Program Based on Annex 1
    Sheba Zaman, Head of Product Specialists and Training Services, Novatek

    11:45 | Q&A
    D1
    Moderator: Malav Parikh, ME, Associate Director, Global Quality Compliance and Systems, Takeda

    10:45 | Using SHERPA (Systematic Human Error Reduction via Process Analysis) to Identify and Reduce Critical Risks Involving Human Factors
    Mimi Ang, MS, Senior Manager, Operational Excellence, Genentech
    Brad Manion, Senior Manager, Operational Excellence, Genentech 

    11:05 | Patient-Administered Therapies: Where Secondary Packaging Plays a Primary Role
    Mark Foster, General Manager, Oliver Design

    11:25 | Integrating Patient Centricity as Part of a Drug Development Program
    Bikash Chatterjee, CEO, Pharmatech Associates

    11:45 | Q&A

    12:15 – 13:45 | Lunch and Tech Talks in Exhibit Hall

    13:45 – 15:15 | Interest Groups

    IG1: Facilities and Engineering

    • IG Leaders
      • Shelley M. Preslar, MBA, President and COO, Azzur Training Center Raleigh LLC
      • Joachim W. Regel, CA Bioprocess Systems Technical Specialist, Merck Chemicals GmbH

    IG2: GXP Auditing & Inspections AND Quality Systems

    • GXP Auditing & Inspections IG Leaders
      • Gabriele Gori, Site Quality Head, Thermo Fisher Scientific
      • Ghada N. Haddad, PhD, Executive Director, Global cGMP and Compliance Auditing Organization, Merck & Co., Inc.
    • Quality Systems IG Leaders
      • Eva M. Urban, MSc, Director QRM and Internal Audits, CSL Behring
      • Michele Simone, Director, Corporate Quality Compliance, Risk Management, and Continual Improvement, Bracco

    IG3: Lyophilization AND Sterile Processing/Parenteral Drug Manufacturing

    • Lyophilization IG Leader: Edward H. Trappler, President, Lyophilization Technology, Inc.
    • Sterile Processing/Parenteral Drug Manufacturing IG Leader: Becky Brewer, VP, Strategic Practices, Quality Executive Partners, Inc.

    IG4: Microbiology/Environmental Monitoring

    • IG Leaders
      • Marc Glogovsky, MS, Senior Consultant - Microbiology, ValSource, Inc.
      • Kurt Jaecques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK

    IG5: Quality Risk Management AND Technology Transfer

    • Quality Risk Management IG Leaders
      • Amanda McFarland, MS, Senior Consultant, ValSource, Inc.
      • Malav Parikh, ME, Associate Director, Global Quality Compliance and Systems, Takeda
    • Technology Transfer IG Leader: Beth J. Haas, MChE, Owner/Consultant, Haas Pharma Consulting

    IG6: Supply Chain Management

    • IG Leader: Amelia (Amy) L. Mutere, MS, Vice President Technical QA and QC, Solid Biosciences

    15:15 – 16:00 | Refreshment Break and Poster Presentations in Exhibit Hall

    16:00 – 17:30 | Concurrent Sessions

    A2
    Moderator: Kristin Valente, PhD, Director, Vaccine Technical Operations, Merck & Co., Inc.

    16:00 | Key Considerations in Biologic Drug Product Process Development
    Sonia Bedi, PhD, Associate Director, Regeneron

    16:20 | Novel Algorithm to Identify Largest Design Spaces
    Thomas Zahel, PhD, Head of Innovation, Körber Pharma

    16:40 | BioPhorum Industry Vision Roadmap 2.0 and Collaboration Case Study: NIMBL-BioPhorum Buffer Stock Blending System
    Nandu Deorkar, PhD, Associate Vice President, Research & Development, BioPhorum Production, Avantor
    Andrea Johnston, PhD, Director, Technology Roadmapping, BioPhorum

    17:00 | Q&A

    B2: Using a Scientific-Based Approach to Disrupt the Status Quo
    Moderator: Kenneth Paddock, Quality Director, Sterility Assurance, Baxter

    Breaking away from the traditional process by doing something different, focusing on improvement, delivering additional value, and looking at the situation in a different light are key aspects to challenging the status quo. This thought- provoking session provides three unique presentations. The first provides a holistic, start-to-finish approach to understand the microbial bioburden risk of the manufacturing process. Next, Pfizer shares a case study on its lessons  learned for how to design a Rapid Micro Method validation strategy, providing tools and general validation approaches. We will then hear from Ed Tidswell, who will shed light on the evaluation of  data from three disparate sources collected over an extended period of time (2008 to 2021) to understand whether there is an industry-wide risk to patients from drug- and device-borne parenterals.

    16:00 | Understanding and Controlling Pre-Sterilization Bio-Burden in Terminally Sterilized Products
    Paul Lopolito, Technical Services Senior Manager, STERIS Corporation

    16:20 | Rapid Micro Methods: How Should We Design and Sustain the Right Validation Strategy? A Case Study Based on A Rapid Sterility Method
    Joanny Salvas, Senior Manager, Pfizer

    16:40 | A Nontrivial Analysis of Patient Safety Risk from Parenteral Drug and Medical Device Borne Endotoxin
    Edward Tidswell, Executive Director AQ, Merck & Co., Inc.

    17:00 | Q&A

    C2: How to Extract Insights From Data, Experience and Knowledge to Enhance and Bring Quality Operations to the Next Level Utilizing State of the Art Technology?
    Moderator: Guido Kremer-van der Kamp, Senior Consultant - Global BioPharm Center of Excellence, Merck KGaA

    Twenty-first century digitalization allows for capturing large amounts of data. But what do we do with all the available data? We need next-generation digital tools to gain insights and actionable information. In this session we share insight on methods and approaches to tackle these challenges to better serve companies’ quality and business needs.

    16:00 | Insights from Mapping API Inspection Deficiencies to the Quality Systems
    Jerry Chapman, MBA, Senior GMP Quality Expert, Redica Systems

    16:20 | Visualizing Document References and Area of Interest Using Graph Theory and Machine Learning
    Mike Salem, Associate Director of Data Science - Quality Assurance, Gilead Sciences

    16:40 | From Data Integrity to Quality Intelligence
    Ulrich Köllisch, Associate Partner, GxP-CC

    17:00 | Q&A

    D2: Not-So-Risky Business: Anticipating, Mitigating, and Managing Supply Chain Risks 
    Moderator: Kate Malachowski, Associate Director, MS&T, Novavax

    In the past few years, the importance and criticality of biopharmaceutical supply chains have been highlighted due to the pandemic and related disruptions. In light of increasing supply chain complexities, companies that take preventative, risk-based actions have trended towards continuity and uninterrupted supply. In this session, we will explore regulatory surveillance as a valuable tool for policy work and external trend identification to drive continuous improvement and proactive compliance, ride the digital transformation wave by delving into a novel risk-scoring system correlating data and yielding risk profiles to alleviate supply chain risks, and apply risk management principles to the procurement of materials essential to enabling patient-centric medicine in the cell and gene therapy space.

    16:00 | The Value of Proactive Regulatory Surveillance: A Company’s Perspective
    Sarah Barkow, PhD, Director External Engagement, Bristol Myers Squibb
    Zankha Patel, Global Quality Director, Regulatory Compliance, Bristol Myers Squibb

    16:20 | Correlating Product and Inspection Data to Anticipate Quality Risks in Your Supply Chain
    Bob Buhlmann, Head of Quality Digital Strategy, AstraZeneca
    Michael de la Torre, Chief Executive Officer, Redica Systems

    16:40 | Same Raw Materials, New Product Risk: Applying Risk Management Principles to Raw Material Fit-For-Function Assessment in A World of Cell and Gene Therapy
    Kara Quinn, Senior Consultant, ValSource, Inc.

    17:00 | Q&A

  • WEDNESDAY, 05 APRIL

    07:00 – 08:15 | Breakfast Session: Developing a Knowledgeable and Skilled Workforce of the Future
    Moderator: Kristin Valente, PhD, Director, Vaccine Technical Operations, Merck & Co., Inc.

    Succeeding in the pharmaceutical industry requires continuous upskilling of the workforce to meet the evolving technical processes and regulatory expectations. This session will highlight how three different groups are accelerating upskilling to create a more agile workforce. First, we will learn how one company enhanced the technical competency of its employees by developing a computer-based training program. Our second talk educates the audience on the process of navigating the regulatory complexity of new modalities, with a case study on Oligonucleotide Therapy. We conclude with a presentation from the Society for Sterility Assurance Professionals (SfSAP). This new organization comprises a diverse group of subject matter experts who have developed a series of open-access learning frameworks for different sterilization modalities.

    07:00 | Capabilities Development for Sterile Manufacturing
    Mauro Giusti, PhD,     Senior Director, Site External Network, Eli Lilly and Company

    07:20 | Overcoming the Regulatory Challenges of Oligonucleotide Therapy CMC
    Janmeet Anant, PhD, Senior Regulatory Consultant, MilliporeSigma

    07:40 | Knowledge, Skills, and Experiences: Competencies for a Sterility Assurance Professional
    James Vesper, PhD, MPH, Director, Learning Solutions, ValSource, Inc.
    Arthur Dumba, Director and General Manager, Society for Sterility Assurance Professionals 

    08:00 | Q&A
    08:30 – 10:00 | ECP Session: PDA Propels - How to Jumpstart Your Career and Get the Most Out of Your PDA Membership and Career
    Moderators: Kate Malachowski, Associate Director, MS&T, Novavax and Tita Tavares, Director, Azzur Group
    08:30 | Things I Had to Learn at Warp Speed in the Era of Project Warp Speed
    Nina Rosso,     Bioprocess Engineer, Novavax

    08:50 | Kelly Waldron, Business Unit Manager/Senior Consultant, Valsource, Inc.

    09:00 | Stephanie Lee, Operations Manager, Amgen

    09:10 | Tita Tavares, Director, Azzur Group

    09:15 | Panel Discussion & Q&A
    Sharif Tusuubira, PhD Candidate, University of Kansas
    Robin Usselman,     Business Development Manager, McMaster University

    08:30 – 10:00 | Interest Groups

    IG7: Annex 1 Implementation

    • IG Leaders
      • Marcia C. Baroni, MBA, VP Enterprise GxP Compliance & Systems, Emergent BioSolutions
      • Rebecca A. Brewer, VP Strategic Practices, Quality Executive Partners, Inc.
      • Gabriele Gori, Site Quality Head, Thermo Fisher Scientific
      • Stephen E. Langille, PhD, Microbiology Consultant, ValSource, Inc.

    IG8: Cell and Gene Therapy/ATMP AND Quality Risk Management

    • Cell and Gene Therapy/ATMP IG Leader: Darius Pillsbury, Senior Consultant, ValSource, Inc.
    • Quality Risk Management IG Leaders
      • Amanda McFarland, MS, Senior Consultant, ValSource, Inc.
      • Malav Parikh, ME, Associate Director, Global Quality Compliance and Systems, Takeda

    IG9: Data Integrity

    • IG Leaders
      • Kir F. Henrici, CEO, The Henrici Group
      • Ulrich Köllisch, Associate Partner, GxP-CC

    IG10: Filtration

    • IG Leaders
      • Maik W. Jornitz, MSEng, CEO, G-CON Manufacturing, Inc.
      • William Peterson, Associate Director of Engineering, Merck & Co., Inc.

    IG11: Process Validation

    • IG Leaders
      • Robert Dream, Managing Director, HDR Company LLC
      • Mauro Giusti, MSc, Senior Director, Site External Network, Eli Lilly and Company

    IG12: Vaccines

    • IG Leader: Jane L. Halpern, Executive Director, IAVI

    10:00 – 10:45 | Refreshment Break and Poster Presentations in Exhibit Hall

    10:45 – 12:15 | Concurrent Sessions

    A3: Accelerating ATMPs into the Future
    Moderator: Peter Makowenskyj, MEng, Director of Design Consulting, G-CON Manufacturing, Inc.

    Novel and advanced therapies are paving the way for treating illnesses in ways that were unimaginable in the past. As a large number of these modalities are new, there are still many unanswered questions in how to optimize the way in which they are manufactured. We have brought together some of the experts in our field to discuss how we can accelerate, optimize, and advance ATMPs into the future.

    10:45 | Accelerating Early Phase Development Through Hybrid Manufacturing
    David Frank, PMP, VP Client Development, Azzur Group

    11:05 | Optimization of Aseptic Manufacturing Risk Mitigation Strategies for ATMPs
    Jeff Odum, CPIP, Practice Lead, ATMPs & Biologics, Genesis AEC
    Jason Rossi, Director, Global Engineering, Cell & Gene Therapy, Catalent

    11:25 | Advances in Gene Editing and the Influence on Novel Therapy Facility Design
    Emily Heffernan, PE, US Director New Process Technology, DPS Group

    11:45 | Q&A

    B3: Educate Like the Future Depends on It: Technology, Strategy, and Implementation
    Moderator: Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

    In this exciting presentation, the speakers will reflect on the criticality of educating our workforce. Dr. Smith and Mr. Scheler will focus on Johnson & Johnson's experience in using Meta-EA (Meta Error Analysis) to proactively create risk profiles for planned cell and gene therapy manufacturing processes. Ms. Ritchey will provide evidence that training should not be considered an activity of the department, but rather a strategy for building workforce competency. Mr. Ayers will demonstrate that it is imperative that personnel on the manufacturing floor understand the manufacturing processes, but also the ‘why’ behind the requirements for producing sterile medicinal products. Each speaker will offer perspectives on technology, strategy and implementation and the factors needed to shape the future of our industry workforce.

    10:45 | Human Factor Control Strategy for Cell and Gene Therapy Manufacturing: Introducing A Frame-By-Frame Risk Profiling and Mitigation Approach
    Sebastian Scheler, MSc, Managing Director and Chief Methodologist, Innerspace GmbH
    Ron Smith, PhD, Global Head, Janssen Microbiology Quality and Sterility Assurance, Johnson & Johnson

    11:05 | Designing a Training Strategy to Drive Human Error Reduction
    Londa Ritchey, Quality Director, PharmaLex

    11:25 | Implementation of a New Educational Platform
    Frederic Ayers, Advisor - Sterility Assurance, Global Parenteral Products Network, Eli Lilly and Company

    11:45 | Q&A

    C3: Analyze This! An Integrated Approach for Optimization & Risk Assessment
    Moderator: Lauren Specchio, Microbiologist (RA III), Baxter

    In simplest terms, a risk is defined as the effect of uncertainty on objectives. Understanding risk and how we can mitigate and incorporate data-driven decisions is key to an assessment. In our first talk, we will be discussing the analytical lifecycle management and the considerations associated with method revision that may be a necessary output of method performance monitoring. This talk will feature examples of analytical method lifecycle management where optimization of system suitability was necessary to ensure both the adequacy of the method's established controls prior to the generation of sample data and how risk assessment is incorporated into method suitability. In our next talk, we will hear about the process of gathering risks and data-driven evidence utilizing a unified approach that integrates process mapping and analysis and history aggregation for lifecycle management. The goal of this process is to achieve a multidimensional knowledge-based approach resulting in a compreshensive picture of the industry. Wrapping up this session is a talk on understanding bias and subjectivity, its impact on risk (particularly hazard identification) and a method to reduce bias and promote creative thinking.

    10:45 | Analytical Lifecycle Management and the Criticality of Method Suitability
    Paul Mason, PhD, Senior Director, Lachman Consultants
    Mrinmoy Nag, PhD, Senior Director, Lachman Consultants

    11:05 | From Risk to Evidence on A Path Towards Knowledge: A Structured Approach
    Rui Almeida, Head MS&T, Valgenesis | 4 Tune Engineering

    11:25 | Creativity, Subjectivity, and Bias in Quality Risk Management
    Andrew O’Connor, Consulting Director, ERA Sciences

    11:45 | Q&A
    D3
    Moderator: Malav Parikh, ME, Associate Director, Global Quality Compliance and Systems, Takeda

    10:45 | Supply Chain Integrity, Sustainability, and Quality: How the Intersection Helps Patients
    James Fries, CEO, Rx-360

    11:05 | How to Accelerate the Supply of Medicines to All Populations Worldwide: A Regulatory Perspective
    Mic McGoldrick, Technical Advocacy and Policy – CMC, Merck & Co., Inc.

    11:25 | Supply Chain Shortages: True Root Causes and Practical Examples
    Stephan Rönninger,     Quality External Affairs, Amgen Inc.
    Emabelle Ramnarine, PhD

    11:45 | Q&A

    12:15 – 13:45 | Lunch and Poster Presentations in Exhibit Hall

    13:45 – 15:15 | P4: Meeting Patients' Needs by Making Safe and Effective Medicines Available
    Moderators: Guido Kremer-van der Kamp, Senior Consultant - Global BioPharm Center of Excellence, Merck KGaA and Diane Paskiet, MS, Director of Scientific Affairs, West Pharmaceutical Services, Inc.

    Chronic illnesses and disease outbreaks, both endemic and pandemic, have influenced therapeutic advancements to meet the needs of patients. As innovative approaches to treatments are progressing, new challenges emerge to the efficient development and manufacturing of quality medicines to deliver to patients. A major concern is the "last mile" in providing patients with critical medicines, especially vaccines requiring cold storage. This session will feature CEPI's efforts to solve this issue with innovative approaches to reducing the need for ultra-cold storage. Advancing treatments will also require a resilient supply chain to ensure the accessibility of safe and effective medicines. The United States Pharmacopeia will provide insight into the identification of supply chain vulnerabilities to avoid disruptions and enable the timely delivery of medicines to patients.

    13:45 | Speed, Access and Quality in Vaccine Development and Manufacturing
    June Kim, PhD,     CMC Lead, CEPI

    14:10 | Drivers of Resilience in the US Pharmaceutical Supply Chain 
    Vimala Raghavendron, MBA,     Senior Director, Informatics Product Development, US Pharmacopeia

    14:35 | Q&A

    15:10 | Closing Remarks from Meeting Co-Chairs
    Amanda McFarland, MS,     Senior Consultant, ValSource, Inc.
    Kenneth Paddock,     Quality Director, Sterility Assurance, Baxter

Networking Opportunities

MONDAY, 03 APRIL

  • 15:00 – 15:30 | Refreshment Break
  • 17:00 – 18:30 | Grand Opening Celebration in Exhibit Hall

TUESDAY, 04 APRIL

  • 10:00 – 10:45 | Refreshment Break and Poster Presentations in Exhibit Hall
  • 12:15 – 13:45 | Lunch and Tech Talks in Exhibit Hall
  • 15:15 – 16:00 | Refreshment Break and Poster Presentations in Exhibit Hall
  • Open Evening | More information coming soon about tours and dining!

WEDNESDAY, 05 APRIL

  • 10:00 – 10:45 | Refreshment Break and Poster Presentations in Exhibit Hall
  • 12:15 – 13:45 | Lunch and Poster Presentation in Exhibit Hall

Highlighted Speakers

Frederic B. Ayers
Frederic B. Ayers
Eli Lilly and Company
Kurt Brorson
Kurt Brorson
Parexel International
Jim (James) M. Fries
Jim (James) M. Fries
Rx-360
Julia Jenkins
Julia Jenkins
Maik W. Jornitz
Maik W. Jornitz
G-CON Manufacturing, Inc.
Amanda McFarland
Amanda McFarland
ValSource, Inc.
Kenneth Paddock
Kenneth Paddock
Baxter
Hari Pujar
Hari Pujar
Flagship Pioneering
Emma Ramnarine
Emma Ramnarine
Ed C. Tidswell
Ed C. Tidswell
Merck & Co., Inc.
Sheba S. Zaman
Sheba S. Zaman
Novatek
View All

Additional Information

  • Call for Abstracts

    Download Call for Papers

    Call for Papers/Abstracts is available now.

    Download

    Abstract Submission

    Call for Papers/Abstracts is available now.

    Submit Abstract
  • Who Should Attend

    Pharmaceutical/Biopharmaceutical Company Industry

    Facilities and Engineering | Manufacturing | Quality Risk Management | Regulatory Affairs

    Job Functions

    Consultant | Director | Executive and Mid-Level Management | Manager/Leader/Supervisor | Manufacturing Application | Project Management | Risk Management | Scientist | Site Head/Plant Manager | Supply Chain | Technical Services

    Departments

    Compliance | Engineering | Executive Management | Information Technology | Laboratory Science | Manufacturing | Product Development | Quality | Research and Development | Regulatory Affairs | Technical Operations | Training | Validation

Got a Question? We have answers

Contact Us

Travel

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

Hyatt Regency New Orleans

601 Loyola Avenue
New Orleans, LA

Make a Reservation
Hyatt Regency New Orleans
  • Accommodations
    The Hyatt Regency New Orleans is the headquarter hotel for the 2023 PDA Annual Meeting!

    Rate: $255 USD for single/double occupancy, plus state and local taxes
    Cut-Off Date: Friday, 03 March 2023 (after this date the discounted PDA rate is no longer guaranteed)
    Check-In: 16:00
    Check-Out: 11:00

    Reservations

    Online: Click on the reservation link above
    Phone: +1 (504) 561-1234, make sure to give the PDA Group Code, G-PDAA, to receive the discounted conference rate

    Individual Cancellation

    72 hours prior to 23:59 local time of the day of arrival to check-in to avoid one night fee. Obtaining and canceling hotel reservations is the responsibility of the meeting participant. Individuals will be responsible for payment of their own cancellation fees.

  • Amenities

    Discover the culture of the Crescent City at Hyatt Regency New Orleans. Centered downtown near Champions Square, Smoothie King Center, and minutes from the historic Mississippi Riverfront. There's no better place from which to explore the eclectic vibrancy of New Orleans.

    Hyatt Regency New Orleans is conveniently located near many popular attractions. They’re only a few minutes walk from the French Quarter and the Arts District. Or hop on the city’s famous streetcars — the Loyola line stops directly outside the hotel.

How to Get Here

By Air

Louis Armstrong New Orleans International Airport (MSY) is approximately 15 miles (24km) from the hotel and all major carriers service this airport. Taxi fares from MSY are approximately $36 one way, not including tip, and will take about 20 minutes.

By Car

Hyatt Regency New Orleans is located at 601 Loyola Avenue, New Orleans, LA 70113. Valet parking is offered at the hotel and there are several nearby parking lots, including the 1301 Girod Parking Garage that connects directly to the hotel. Contact Merit Parking to confirm pricing; +1 (504) 561-0575.

Other Options

Hyatt Regency New Orleans is happy to partner with a local shuttle service to make your trip to and from the Louis Armstrong New Orleans International Airport easy. To learn more, and reserve your spot at least 24 hours prior to your flight arrival time, visit airportshuttleneworleans.com/portals/hyatt-regency-new-orleans.

Directions

Registration Fees

Early Registration
REGISTRATION TYPE BY 05 FEBRUARY
Member $1,995
Non-Member $2,395
Gov./Health Authority/Academic (Member Only) $795
Early Career Professional (Member Only) $1,295
Student (Member Only) $495
Regular Registration
REGISTRATION TYPE AFTER 05 FEBRUARY
Member $2,495
Non-Member $2,895
Gov./Health Authority/Academic (Member Only) $895
Early Career Professional (Member Only) $1,395
Student (Member Only) $595

Group Registration Discount: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].

Sponsors

Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information

Featured Exhibitors

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information
Exhibitor Standard Contract Clause

Media Partners

Related Events

Related Events

Contact

Program Inquiries
Exhibition Inquiries
Training Course Inquiries

Tel: +1 (301) 656-5900
[email protected]

Tel: +49 (0) 30 43 655 08-10
[email protected]

Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially